Loading
Exact Sciences' tissue test for advanced solid tumours that reads every gene's DNA and RNA and compares the tumour with the patient's normal DNA.
OncoExTra is Exact Sciences' comprehensive genomic profiling test for advanced, metastatic, refractory, relapsed or recurrent solid tumours. It sequences the whole exome of the tumour against a matched normal sample and the whole transcriptome of the tumour, and reports mutations and fusions associated with FDA-approved therapies, tumour mutational burden and microsatellite status, and clinical trial options. Exact Sciences cites the 2021 validation of GEM ExTra as the test's own validation: that assay detects single-nucleotide variants, insertions and deletions, focal copy number changes and the TERT promoter region, and its RNA sequencing finds fusions and transcripts such as AR-V7, EGFR vIII and MET exon 14 skipping. In a retrospective analysis of 1,509 reports that Exact Sciences quotes, 83.9% showed at least one clinically actionable variant. The test was developed by Genomic Health, an Exact Sciences subsidiary, is performed at its Phoenix laboratory, and has not been cleared or approved by the FDA.
Whole-exome DNA sequencing of the tumour and of a matched normal sample, so inherited variants can be subtracted, plus whole-transcriptome RNA sequencing of the tumour for gene fusions and selected abnormal transcripts.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"OncoExTra" OR ABSTRACT:"OncoExTra" OR TITLE:"Exact Sciences OncoExTra" OR ABSTRACT:"Exact Sciences OncoExTra") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about OncoExTra, not a curated reading list.
Shares AR-V7 splice variant, TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), Next-generation sequencing (NGS), Whole-exome & whole-genome sequencing and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Comprehensive genomic profiling and the tag test.
Shares NRG1 gene fusion, NTRK1/2/3 gene fusion, Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/